It's How Medicine Should Be®
<< Previous | New Search | Return to Search Results | Next >>

Physician Profile


call (888) 352-RUSH for help arranging an appointment

William T. Leslie, MD

Patient Feedback
  • Oncology, Medical
  • Hematology
  • Internal Medicine
  • Geriatric Medicine
Board Certification:
  • Medical Oncology
  • Hematology
  • Internal Medicine
Faculty Rank: Assistant Professor
Medical or Graduate Education: Oregon Health & Science University School of Medicine
Residency: University of Illinois Medical Center - Internal Medicine
Fellowship: Rush University Medical Center - Hematology/Oncology
Clinical Expertise:
  • Bile duct cancer
  • Carcinoid tumor
  • Gallbladder cancer
  • Kaposi's sarcoma
  • Liver cancer
  • Pancreatic cancer
  • Stomach cancer
Research Interests:
  • Gastrointestinal cancer
Google Map
Google Map
Google Map
Google Map

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to Listings go back five years.

  1. Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.
    Brown JP, Morin S, Leslie W, Papaioannou A, Cheung AM, Davison KS, Goltzman D, Hanley DA, Hodsman A, Josse R, Jovaisas A, Juby A, Kaiser S, Karaplis A, Kendler D, Khan A, Ngui D, Olszynski W, Ste-Marie LG, Adachi J
    Can Fam Physician
    2014 Apr
  2. Risk factors for post-injury mental health problems.
    Sareen J, Erickson J, Medved MI, Asmundson GJ, Enns MW, Stein M, Leslie W, Doupe M, Logsetty S
    Depress Anxiety
    2013 Apr
  3. Investigation of repeatability in hip fracture risk predicted by DXA-based finite element model.
    Luo Y, Leslie W
    Conf Proc IEEE Eng Med Biol Soc
  4. Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas.
    Davis M, Conlon K, Bohac GC, Barcenas J, Leslie W, Watkins L, Lamzabi I, Deng Y, Li Y, Plate JM.
    J Immunother. 2012
    2012 Oct
  5. A Patient With Metastatic Adenocarcinoma of the Jejunum Who Had a Prolonged Complete Response to FOLFOX.
    Lai S, Leslie W.
    Gastrointest Cancer Res. 2012
    2012 Mar
    5(2):71-2. No abstract available.
  6. Successful treatment of anal carcinoma with Paclitaxel, Cisplatin, and radiotherapy in a patient who developed a coronary syndrome from 5-fu.
    Garg S, Abrams RA, Leslie WT.
    Gastrointest Cancer Res. 2012
    2012 Jul
    5(4):135-6. No abstract available.
  7. Treatment of recurrent pediatric gastrointestinal stromal tumors.
    Dave M, Jimenez A, Evans K, Leslie W.
    Gastrointest Cancer Res. 2012
    2012 Jul
    5(4):139-40. No abstract available.
  8. Long-term remission of paroxysmal nocturnal hemoglobinuria following chemoimmunotherapy for non-Hodgkin lymphoma.
    Lai S, Venugopal P, Leslie W.
    Clin Adv Hematol Oncol. 2012
    2012 Feb
    10(2):134-6. No abstract available.
  9. Prognostic Significance of Carbohydrate Antigen 19-9 in Unresectable Locally Advanced Pancreatic Cancer Treated With Dose-Escalated Intensity Modulated Radiation Therapy and Concurrent Full-Dose Gemcitabine: Analysis of a Prospective Phase 1/2 Dose Escalation Study.
    Vainshtein JM, Schipper M, Zalupski MM, Lawrence TS, Abrams R, Francis IR, Khan G, Leslie W, Ben-Josef E.
    Int J Radiat Oncol Biol Phys. 2012
    2012 Dec 19. doi:pii: S0360-3016(12)03817-5. 10.1016/j.ijrobp.2012.11.020. [Epub ahead of print]
  10. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.
    Ben-Josef E, Schipper M, Francis IR, Hadley S, Ten-Haken R, Lawrence T, Normolle D, Simeone DM, Sonnenday C, Abrams R, Leslie W, Khan G, Zalupski MM.
    Int J Radiat Oncol Biol Phys. 2012
    2012 Dec 1
    84(5):1166-71. doi: 10.1016/j.ijrobp.2012.02.051. Epub 2012 Apr 27.
  11. A patient with necrobiotic xanthogranuloma presenting with an anterior mediastinal mass, plasma cell dyscrasia, and a lymphoproliferative disorder.
    Chen KY, Leslie W, Mahon B, Venugopal P.
    Clin Adv Hematol Oncol. 2011
    2011 Sep
    9(9):696-700. No abstract available.
  12. Prolonged neutropenia after neoadjuvant radiation therapy and chemotherapy using oxaliplatin and capecitabine for rectal cancer.
    McFarland DC, Leslie WT.
    Gastrointest Cancer Res. 2011
    2011 Jan
    4(1):33-5. No abstract available.
  13. An Epstein-Barr virus-associated smooth muscle tumor successfully treated with surgical resection: a case report and literature review.
    Cela I, Shah NB, Bradly D, Loew J, Leslie W.
    Clin Adv Hematol Oncol. 2010
    2010 Jun
    8(6):423-6. Review. No abstract available.
  14. Neoadjuvant treatment of rectal gastrointestinal stromal tumors with imatinib.
    Turner J, Batus M, Leslie W, Coogan C, Saclarides TJ.
    Am Surg. 2010
    2010 Aug
    76(8):E110-2. No abstract available.
  15. Management of a patient with borderline resectable pancreatic cancer. Case report and review.
    Shah AP, Strauss JB, Leslie WT, Shah A, Mahon B, Abrams RA.
    Oncology (Williston Park). 2008
    2008 Nov 30
    22(13):1524-9. Review.
  16. Localized bone disease as a presentation of hairy cell leukemia.
    Karmali R, Farhat M, Leslie W, McIntire MG, Gregory S.
    Clin Adv Hematol Oncol. 2008
    2008 Apr
    6(4):290-4. No abstract available.
  • (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
  • View Transcript
Patient feedback information is available for physicians employed by Rush University Medical Center who have received 30 or more patient surveys. Responses are measured on a scale of 1 to 5, with 5 being the best score.
Number of Patient Surveys
Friendliness/courtesy of the care provider
Explanations the care provider gave you about your problem or condition
Concern the care provider showed for your questions or worries
Likelihood of your recommending this care provider to others
Care provider's efforts to include you in decisions about your treatment
Information the care provider gave you about medications
Instructions the care provider gave you about follow-up care
Your confidence in this care provider
Degree to which care provider talked with you using words you could understand
Amount of time the care provider spent with you
For more information about patient feedback, see the Quality Care section of the Rush University Medical Center website.